Mizuho Increases Target Price on Medtronic (MDT) to $100 From $98

Medtronic continues to hold strong in the competitive stock market, as Mizuho has raised its target price on the medical device company’s stock to $100 from $98. This revision reflects increased confidence in Medtronic’s growth trajectory and its ability to navigate current economic conditions. 

As investors look for resilient healthcare and AI stocks, Medtronic is once again in the spotlight for its consistent performance and steady product pipeline.

Why Medtronic Remains a Market Leader

Founded in 1949, Medtronic has grown into one of the world’s largest medical device companies. With operations in over 150 countries and a portfolio spanning cardiac devices, surgical robotics, diabetes management, and neurological treatments, its global footprint is difficult to ignore. Medtronic continues to leverage AI technologies in diagnostics, robotic surgery, and remote patient monitoring. This is strengthening its presence in the AI stock space.

Its performance, even during market turbulence, is a testament to its robust business model. The company’s diversified portfolio allows it to withstand industry headwinds and economic uncertainties. This makes it an attractive pick for stock research analysts and long-term investors.

Mizuho’s Outlook: Why the Target Was Raised

On July 16, 2025, Mizuho Securities revised its outlook for Medtronic, lifting the price target to $100, citing stable earnings potential and clarity around product approvals. Analyst Anthony Petrone maintained a Buy rating on the stock. The adjustment comes after Medtronic reported solid results in its recent earnings report, highlighting strong momentum in the Cardiovascular and Neuroscience segments.

The company’s free cash flow performance and a focus on operational efficiency have also supported Mizuho’s bullish sentiment. As healthcare demands continue to grow globally, Medtronic’s innovation in minimally invasive procedures and chronic disease management provides multiple levers for growth.

Strong Performance in Cardiovascular Segment

Medtronic’s Cardiovascular Portfolio, which includes defibrillators, pacemakers, and heart valves, has seen a recovery in demand post-pandemic. With elective surgeries returning to pre-pandemic levels, revenue from these segments has improved. The growth of its transcatheter aortic valve replacement (TAVR) products and atrial fibrillation solutions has further cemented its leadership in the cardiac space.

Surgical Robotics: A Game-Changer in Medtech

Medtronic is also making waves in robotic-assisted surgery, a segment previously dominated by companies like Intuitive Surgical. The launch of Hugo, Medtronic’s surgical robot, is designed to compete globally in this growing field. It incorporates AI-powered analytics and data integration to assist surgeons with precision and decision-making.

Hugo’s entry into the market shows Medtronic’s dedication to adopting cutting-edge technologies, and early feedback from hospital systems indicates promising adoption trends. This further fuels optimism around long-term revenue streams.

Medtronic’s Role in the AI and Healthcare Innovation Space

The convergence of artificial intelligence and healthcare has given rise to a new class of AI stocks, and Medtronic sits at the intersection of this innovation. It has invested heavily in AI-based predictive models, remote patient monitoring, and machine learning to improve diagnostic accuracy and patient outcomes.

In collaboration with Blackford Analysis and other health-tech partners, Medtronic is integrating AI into imaging systems and chronic disease tracking. These efforts are expected to generate new revenue and improve operational efficiency.

Stock Market Trends: How Medtronic Holds Up

Despite overall market volatility, Medtronic stock (MDT) has remained relatively stable. It currently trades near $83 (as of the last update), with analysts seeing upside potential following the recent price target adjustment. The dividend yield of over 3% also attracts income-focused investors.

In comparison to volatile tech and AI startups, Medtronic offers a defensive yet innovative profile. For those looking at stock research from a balanced-risk perspective, Medtronic provides a solid case for both growth and stability.

Regulatory Developments and Global Expansion

One of the reasons behind Medtronic’s resilience is its ability to gain regulatory approvals across multiple jurisdictions. The company’s regulatory filings and approvals in the U.S., Europe, and Asia-Pacific regions reflect its compliance strength and operational scale.

Furthermore, its focus on emerging markets, particularly India and China, allows it to tap into the rising demand for chronic care solutions. These growth vectors offer long-term promise for investors looking for geographic diversification in their portfolios.

Risks to Watch

No stock is without risk, and investors must be cautious of several factors. Supply chain pressures, regulatory hurdles, and competition in the robotic surgery field could impact performance. Additionally, macroeconomic factors such as currency headwinds and geopolitical instability may weigh on international operations.

However, Medtronic’s size, innovation capacity, and established distribution channels help it to navigate these risks effectively.

Conclusion: Is Medtronic Still a Buy?

With Mizuho increasing its target price and maintaining a Buy rating, Medtronic continues to be a strong candidate for healthcare and AI stock portfolios. Its deep R&D pipeline, global presence, and focus on advanced technology keep it positioned for long-term success. 

For investors performing stock research, MDT presents a well-balanced opportunity with upside potential. As the healthcare sector evolves, Medtronic is not just keeping up; it’s helping lead the way.

FAQs

Disclaimer:

This content is made for learning only. It is not meant to give financial advice. Always check the facts yourself. Financial decisions need detailed research.